Oxford, UK – 30 October 2009. OGT, the pioneer of microarray based technologies, has introduced the high resolution CytoSure® DMD array. Featuring a 4x44k format and dense probe coverage of the DMD gene region, this new array offers increased confidence in detecting deletions and duplications within the DMD gene.
OGT’s bioinformatics expertise together with extensive input from Emory Genetics Laboratory and the array manufacturing precision of Agilent Technologies ensures confidence in quality and performance. The CytoSure DMD array has undergone a process of empirical testing and optimisation to provide probe sets of extremely high sensitivity and specificity. Average exon probe spacing of 10 bp (106 bp within introns) ensures excellent resolution. As a result the entire DMD gene is covered on a single 44,000 feature array, which enables 4 full arrays per slide, maximising cost-efficiency by reducing the cost per sample.
John Anson, Research and Development Director at OGT, stated, “By combining Emory Genetics Laboratory and OGT’s expertise in microarray design we believe that we are bringing a powerful tool to the market that will improve our understanding of the deletions and duplications that can occur within the DMD gene. We hope that the CytoSure DMD array will contribute to a better understanding of the genetic basis of the muscular dystrophies and will ultimately lead to the development of new diagnostic tools and therapeutic approaches.”
The CytoSure DMD array adds to OGT’s comprehensive portfolio of products and services, which together provide a complete solution to running oligo aCGH in the laboratory, from set-up to result. Manual processing and analysis of the CytoSure DMD array is straightforward using the CytoSure DMD array, CytoSure Genomic DNA labelling kit and the comprehensive new CytoSure Interpret Software. For higher throughput applications, the CytoSure DMD array is fully compatible with SciGene workflow automation products (now distributed in Europe by OGT).
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
Read
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure® v3 vs traditional array design.
Read
During these unprecedented times, OGT remains committed and ready to support you...
Read
Reinforcing collaboration toward the realisation of genomic medicine in the area of ophthalmic disorders.
Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.
Read
CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.
Read
Sysmex, a Japanese in vitro diagnostic company, will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain.
Read
CytoSure® FH Panels enable streamlined investigation of familial hypercholesterolemia (FH) and customisation of content.
Read
Workshop at ESHG explores the power of exon-focused microarrays in enhancing genetic syndrome research.
Read
New CytoSure® Constitutional v3 +LOH array delivers comprehensive genetic analysis of developmental delay disorders, with content covering 502 targeted genes.
Read
License grants Baylor Miraca use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology.
Read
White paper describes the experiences of Dr Tracey Lewis and Dr Emily Farrow with OGT’s CytoSure Medical Research Exome Array.
Read
Strategic realignment of OGT commercial operations to fuel further growth in its high value genomics products portfolio.
Read
The presentation, entitled ‘The Next Generation of Microarrays: Identifying a Broader Range of Genetic Syndromes Using Exon–Focussed Array Designs’, took place at the ESHG conference in Glasgow, UK.
Read
Unique CytoSure® Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders (DDD) study data.
Read
License gives OGT access to data from the Deciphering Developmental Disorders (DDD) study, which will be used to develop its CytoSure® Constitutional v3 range.
Read
White paper explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure® ISCA 8x60k platform.
Read
Proprietary OGT microarray technology will allow clinical laboratories to utilise existing microarray equipment to offer in-house NIPT.
Read
Developed with leading molecular genetics experts at Emory University, the new array is highly targeted and exon-focussed, enabling the accurate detection of medical research relevant microdeletions and microduplications.
Read
New application note details the technical evaluation of two DNA labelling kits, where OGT’s CytoSure® Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.
Read
New white paper provides researchers to discover how, when used alongside sequencing, microarrays play a vital role in delivering accurate detection of point mutations and single exon copy number aberrations.
Read
Innovative new features further facilitate and standardise the data analysis workflow in order to deliver rapid access to meaningful results.
Read
Expanded range of CytoSure™ Molecular Arrays now enables detection of CNV in genes associated with over 20 genetic disorders, including cardiovascular, inherited eye, intellectual disability and neuromuscular disorders, as well as a range of inherited cancers.
Read
Two-year agreement for the supply of oligo-based arrays for cytogenetics covers a consortium of four UK NHS Genetics Labs.
Read
New array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb.
Read
New array combines long oligo aCGH probes with fully validated SNP content, providing the superior detection of both CNVs and loss of heterozygosity (LOH) on a single chip.
Read
App note aims to support researchers in navigating a combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH) on a single array.
Read
The licence agreement agreed with the Cancer Cytogenomics Microarray Consortium (CCMC) is to design a whole genome, cancer-specific microarray.
Read
Database is comprised of more than 10 million oligonucleotide probes designed to the latest release of the human genome.
Read
By utilising an entirely new relational database design, the software now allows sample data to be stored and analysed in accordance to its relationship with other data.
Read
Array combines array comparative genomic hybridisation (aCGH) probes, endorsed by the International Standards for Cytogenomic Arrays (ISCA) Consortium, with fully validated single nucleotide polymorphism (SNP) content.
Read
CytoSure® Haematological Cancer +SNP array is optimised for the study of the haematological malignancies CLL and Multiple Myeloma, as well as MPN and MDS.
Read
New DNA microarrays utilise a unique collection of probes for detecting CNVs within genes associated with a variety of rare disease disorders.
Read
Product range now includes high-throughput genomic DNA labelling kits and sample tracking spike-ins
Read
Accreditation extends to all data generation and security procedures, and acknowledges that data confidentiality, availability and integrity is carefully managed and controlled.
Read
Groundbreaking CytoSure® ISCA UPD 4 x 180k array allows simultaneous detection of DNA copy number variation (CNV) and whole chromosome uniparental disomy (UPD).
Read
OGT's CytoSure® Interpret Software can now seamlessly transfer aCGH aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics platform.
Read
The three new powerful arrays focus on disease and syndrome-associated genome regions, in addition to offering whole genome coverage.
Read
CytoSure® Interpret software delivers faster and easier translation of oligo aCGH data into meaningful results.
Read
The publication published in Nature is entitled ‘Origins and Functional Impact of Copy Number Variation in the Human Genome.’
Read
The Center for Human Genetics at Katholieke Universiteit Leuven, Belgium, has begun assessment of OGT's CytoSure arrays for use in prenatal diagnostic research.
Read
More than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium have been processed by OGT.
Read
The Genomic DNA Labelling Kit offers a fast and simple protocol and is optimised for OGT’s CytoSure® family of high resolution oligonucleotide arrays.
Read
OGT and Wellcome Trust Sanger Institute sign collaboration agreement to develop a single platform microarray to test for genetic defects in unborn children.
Read
Visit USA site
Visit Canada site
